bevacizumab Sponsor: ARCAGY-GINECO Principal Investigator : Pr Jean - PowerPoint PPT Presentation

Aug 20, 2022 •293 likes •339 views

AT ezolizumab and A vastin in LA te recurre NT diseas E A randomized, double blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by

AT ezolizumab and A vastin in LA te recurre NT diseas E A randomized, double blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab Sponsor: ARCAGY-GINECO Principal Investigator : Pr Jean Emmanuel Kurtz; CHRU Strasbourg Scientific Coordinator: Pr Eric Pujade-Lauraine
Recruitment curve 450 400 350 300 92 randomized patients / 119 screened 250 (only in France) 200 150 100 50 0 oct-16 janv-17 apr-17 juil-17 oct-17 janv-18 apr-18 juil-18 oct-18 janv-19 Cumul screening Cumul rando Rando theo 120 100 80 32 sites actives / 39 sites opened Nb screening 60 Cumul screening Nb rando 40 Cumul rando 20 0
Safety analyses ▪ 1 st IDMC on 36 first patients who have received 1 cycle has been performed on March 2017  There are no safety concern in comparison with chemotherapy alone ▪ 2 nd IDMC on 45 first patients who have received 2 cycles is planned in June 2017 Amendement Protocol was amended in April 2017 following the 1 st IDMC. Approvals are expected in June. Launch on an international level planned in September 2017

Download Presentation

Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend

UPDATE Niraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with

NSGO EARLY PHASE CLINICAL TRIALS UPDATE Niraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with Homologous Recombination Deficient (HRD) platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.

339 views • 15 slides

A randomized phase II study of paclitaxel/carboplatin/bevacizumab,

A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA; stage IV or recurrent endometrial cancer, GOG-86P

482 views • 15 slides

NSGO CLINICAL TRIALS IN OVARIAN CANCER UPDATE Niraparib and niraparib-bevacizumab combination

NSGO CLINICAL TRIALS IN OVARIAN CANCER UPDATE Niraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with Homologous Recombination Deficient (HRD) platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal

240 views • 11 slides

NCT01167712 a GOG/NRG Trial (GOG 252) Joan L. Walker; Mark F Brady; Paul A DiSilvestro; Keiichi

A PHASE III CLINICAL TRIAL OF BEVACIZUMAB WITH IV VERSUS IP CHEMOTHERAPY IN OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CARCINOMA NCI-SUPPLIED AGENT(S): BEVACIZUMAB (NSC #704865, IND #7921 ) NCT01167712 a GOG/NRG Trial (GOG 252) Joan L. Walker;

485 views • 22 slides

Phase 2 Randomization: 1:1:1 Switch over to ARM A n=132 Treat to Niraparib Bevacizumab

ENGOT-OV24-NSGO/AVANOVA Phase 2 Randomization: 1:1:1 Switch over to ARM A n=132 Treat to Niraparib Bevacizumab PD/toxicity 300mg OD d1-21 15mg/kg q3w Platinum- sensitive Ovarian Cancer ARM B Treat to Randomize Niraparib

319 views • 7 slides

IMbrave150 Trial of Atezolizumab + Bevacizumab vs Sorafenib as First-Line Treatment for Patients

Patient-Reported Outcomes From the Phase 3 IMbrave150 Trial of Atezolizumab + Bevacizumab vs Sorafenib as First-Line Treatment for Patients With Unresectable Hepatocellular Carcinoma Peter R. Galle, 1 Richard S. Finn, 2 Shukui Qin, 3 Masafumi

1.68k views • 18 slides

AURELIA: A randomized phase III trial evaluating bevacizumab combined with chemotherapy for

AURELIA: A randomized phase III trial evaluating bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer Eric Pujade-Lauraine 1 , Felix Hilpert 2 , Batrice Weber 3 , Alexander Reuss 4 , Andres Poveda 5 , Gunnar

557 views • 17 slides

Phase Ib Study Results: Subgroup Efficacy Analysis of Atezolizumab + Bevacizumab in Patients With

Phase Ib Study Results: Subgroup Efficacy Analysis of Atezolizumab + Bevacizumab in Patients With Previously Untreated, Unresectable Hepatocellular Carcinoma Kyung-Hun Lee, 1 Baek-Yeol Ryoo, 2 Chih-Hung Hsu, 3 Kazushi Numata, 4 Stacey Stein, 5

452 views • 15 slides

Super-selective Blood Brain Barrier Disruption and Intra-arterial Infusion of Bevacizumab

HOWARD A. RIINA, MD PROFESSOR AND VICE CHAIRMAN RESIDENCY PROGRAM DIRECTOR DEPARTMENT OF NEUROSURGERY NEW YORK UNIVERSITY SCHOOL OF MEDICINE Super-selective Blood Brain Barrier Disruption and Intra-arterial Infusion of Bevacizumab

784 views • 55 slides

Long term response to Bevacizumab to an initially resistant glioblastoma No conflict of

ESMO Preceptorship Programme Brain tumors Athens 28-29 september Tarek ASSI Institut Gustave ROUSSY - Paris Long term response to Bevacizumab to an initially resistant glioblastoma No conflict of interests ESMO PRECEPTORSHIP

473 views • 9 slides

hepatocellular carcinoma: Phase 3 results from IMbrave150 Ann-Lii Cheng, 1 Shukui Qin, 2 Masafumi

Atezolizumab + bevacizumab vs sorafenib in patients with unresectable hepatocellular carcinoma: Phase 3 results from IMbrave150 Ann-Lii Cheng, 1 Shukui Qin, 2 Masafumi Ikeda, 3 Peter R. Galle, 4 Michel Ducreux, 5 Andrew X. Zhu, 6 Tae-You Kim, 7

328 views • 17 slides

$Metastatic Refractory Gestational Trophoblastic Neoplasia JOHN R. LURAIN, MD JOHN I. BREWER$

Metastatic Refractory Gestational Trophoblastic Neoplasia JOHN R. LURAIN, MD JOHN I. BREWER

TRC 105 +/- Bevacizumab for Patients with Metastatic Refractory Gestational Trophoblastic Neoplasia JOHN R. LURAIN, MD JOHN I. BREWER TROPHOBLASTIC DISEASE CENTER DEPARTMENT OF OBSTETRICS AND GYNECOLOGY ROBERT H. LURIE COMPREHENSIVE CANCER

276 views • 24 slides

ENGOT model C (AZ) Lead group: GINECO Co-lead group : ISGO (Pr J Korach) Rationale Only 2

ENGOT model C (AZ) Lead group: GINECO Co-lead group : ISGO (Pr J Korach) Rationale Only 2 targeted therapy in OC: bevacizumab and olaparib In contrast to chemotherapy: only one shot for each (if no contra-indication and if BRCAm for

445 views • 7 slides

The Cure-Death Model An approach to increase efficiency of clinical endpoint evaluations DAGStat

Introduction The Cure-Death Model RL test Application Simulation Summary Current Work The Cure-Death Model An approach to increase efficiency of clinical endpoint evaluations DAGStat G ottingen 2016 Harriet Sommer, Martin Wolkewitz,

241 views • 23 slides

Research in a multidimensional world Pat Bazeley Adjunct Professor, TReSI group, Western Sydney

Research in a multidimensional world Pat Bazeley Adjunct Professor, TReSI group, Western Sydney University www.researchsupport.com.au The phenomena we study have both qualities and quantities They can also be assessed in terms of time or

416 views • 28 slides

Directed polymer in -stable Random Environments Roberto Viveros IMPA. Rio de Janeiro-Brazil

Directed polymer in -stable Random Environments Roberto Viveros IMPA. Rio de Janeiro-Brazil JULY 23, 2019 Roberto Viveros Directed polymer in -stable Random Environments Chemical background Roberto Viveros Directed polymer in -stable

495 views • 37 slides

DNA fluorescence probes based on N -[5-(11-functionalised-undecylamino)- 9 H -benzo[ a

[C018] DNA fluorescence probes based on N -[5-(11-functionalised-undecylamino)- 9 H -benzo[ a ]phenoxazin-9-ylidene]propan-1-aminium chlorides Sarala Naik, M. Sameiro T. Gonalves and Paulo J. G. Coutinho a * Centro de Qumica, Universidade do

352 views • 6 slides

1 = MDL-FOREM0000904 PRODNO = MDLDVD001 CD_NAME : CONFIDENTIAL TREATMENT : Mitchner, Natasha

1 = MDL-FOREM0000904 PRODNO = MDLDVD001 CD_NAME : CONFIDENTIAL TREATMENT : Mitchner, Natasha FROM : 'Christina Goetjen'; 'Jeff Lawrence'; 'Bill Heydorn' TO = 11/20/2001 DATE : 03:49:24 PM TIME : Wagner Hot Topics slides SUBJECT : Outlook

413 views • 12 slides

Working With Humans: Effects and Ethics Some effects to be aware of when doing human-subjects

Working With Humans: Effects and Ethics Some effects to be aware of when doing human-subjects research. The role of ethics in evaluating interfaces with the help of human subjects. Hawthorne Effect The basic idea behind the Hawthorne Effect

148 views • 11 slides

Post-Floorplanning Power/Ground Ring Synthesis for Multiple-Supply-Voltage Designs International

Post-Floorplanning Power/Ground Ring Synthesis for Multiple-Supply-Voltage Designs International Symposium on Physical Design March 30, 2009 Wan-Ping Lee Diana Marculescu Yao-Wen Chang Outline Introduction Problem Formulation

1.17k views • 31 slides

11/27/2006 Massachusetts Institute of Technology Motivation Would like robotic manipulators

11/27/2006 Massachusetts Institute of Technology Motivation Would like robotic manipulators to be able to Manipulator Path Planning with Obstacles operate in cluttered environments using Disjunctive Programming ACC06 Short Paper Lars

236 views • 9 slides

Universit di Roma La Sapienza Goals and motivations complete cancellation of gravity

ICRA 2010 Workshop on New Variable Impedance Actuators for the Next Generation of Robots Anchorage, May 3, 2010 Dynamic Gravity Cancellation in Robots with Flexible Transmissions: constant, nonlinear, and variable stiffness Alessandro De Luca

826 views • 25 slides

fifteen wood construction: connections Wood Connections 1 Elements of Architectural Structures

E LEMENTS OF A RCHITECTURAL S TRUCTURES : F ORM, B EHAVIOR, AND D ESIGN ARCH 614 D R. A NNE N ICHOLS S PRING 2019 lecture fifteen wood construction: connections Wood Connections 1 Elements of Architectural Structures S2019abn Lecture 15

478 views • 15 slides

Humanoid Robotics Inverse Kinematics and Whole-Body Motion Planning Maren Bennewitz 1

Humanoid Robotics Inverse Kinematics and Whole-Body Motion Planning Maren Bennewitz 1 Motivation Plan a sequence of configurations (vector of joint angle values) that let the robot move from its current configuration to a desired goal

717 views • 52 slides